Avanza Fonder AB Purchases Shares of 25,810 Hologic, Inc. (NASDAQ:HOLX)

Avanza Fonder AB acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 25,810 shares of the medical equipment provider’s stock, valued at approximately $1,861,000.

Several other institutional investors have also made changes to their positions in the business. Wolff Wiese Magana LLC bought a new position in Hologic during the third quarter worth about $25,000. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter worth approximately $26,000. Groupama Asset Managment boosted its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic in the second quarter valued at $37,000. Finally, First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 0.3 %

Shares of NASDAQ HOLX opened at $69.73 on Friday. Hologic, Inc. has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The firm has a market capitalization of $15.82 billion, a P/E ratio of 20.94, a P/E/G ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company’s 50 day simple moving average is $74.84 and its 200 day simple moving average is $78.37.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.89 earnings per share. On average, analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.75% of the stock is owned by insiders.

Analyst Ratings Changes

HOLX has been the topic of several analyst reports. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Wolfe Research assumed coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Finally, UBS Group boosted their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.